Outcome criteria such as massive transfusion are inadequate for matching and result in questionable conclusions.

Klaus Görlinger,S. Kozek‐Langenecker,D. Spahn
DOI: https://doi.org/10.1097/01.ta.0000436142.47256.32
2013-10-01
Journal of Trauma and Acute Care Surgery
Abstract:by admission systolic blood pressure (SBP). In the subgroup of trauma patients presenting with SBP of 75 mm Hg or less, all-cause 28-day mortality was 30.6% (478 of 1,562) TXAversus 35.1% (562 of 1,599) placebo (RR, 0.87; 99% confidence interval 0.76Y0.99). The CRASH-2 mortality rate is significantly higher than the 30-day mortality rate (11.4%) in the analysis cohort of the Prospective, Observational, Multicenter, Major Trauma Transfusion (PROMMTT) trial, performed in 10 Level I trauma centers in the United States with all participating centers with massive transfusion protocols in place. The PROMMTT study also documented that earlier infusion of higher plasma and platelet ratios was associated with decreased mortality within 6 hours of admission, during which 81% of the hemorrhagic deaths had occurred. Since we do not have data regarding plasma and platelet transfusions in the CRASH-2 trial, it is not possible to determine if this was a confounding factor in the study. A recent publication from the CRASH-2 investigators used the trial data to examine the effect of TXA on death due to bleeding by geographic region. Although there was no evidence of heterogeneity in the effect of TXA by region, country-specific estimates documented that the largest numbers of death averted with TXAuse in traumawould be in India and China. We believe that our recommendation to use TXA ‘‘in adult trauma patients with known fibrinolysis by TEG or with known predictors of fibrinolysis or in severe hemorrhagic shock (SBP e 75 mm Hg) if TEG is not available’’ remains valid, based on the evidence to date.
What problem does this paper attempt to address?